UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007377
Receipt number R000008690
Scientific Title Comparison of the Safety and Efficacy of the Management of Pacemaker Patients Followed-up via Home Monitoring vs. Conventional In-office Follow-ups
Date of disclosure of the study information 2012/02/24
Last modified on 2014/07/03 17:45:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of the Safety and Efficacy of the Management of Pacemaker Patients Followed-up via Home Monitoring vs. Conventional In-office Follow-ups

Acronym

atHome Study

Scientific Title

Comparison of the Safety and Efficacy of the Management of Pacemaker Patients Followed-up via Home Monitoring vs. Conventional In-office Follow-ups

Scientific Title:Acronym

atHome Study

Region

Japan


Condition

Condition

Arrhythmia

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to demonstrate that the BIOTRONIK Home Monitoring system is able to reduce office follow-up visits without compromising patient safety.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

The purpose of the primary endpoint is to compare the composite safety endpoint, Safety Event Rate (SER) which includes death, incidence of strokes and cardiovascular related serious adverse events requiring surgical interventions (e.g. device explants or lead revision) between the two groups. If the safety event rate for Group 1 is equivalent (non-inferior) to that of Group 2, patient follow-up by Home Monitoring is considered safe.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Remote monitoring only group (HM)

Interventions/Control_2

Remote monitoring + conventional in-office follow-up group

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

*Indicated for IPG implantation under Japanese guidelines
*Implanted with a BIOTRONIK IPG with Home Monitoring within the last 45 days, or being considered for implantation
*Able to utilize HM system throughout the study
*Ability to give informed consent
*Geographically stable and able to return for follow-ups for 27 months
*Over 20 years old
*Patient able to understand and follow the procedure stated in protocol

Key exclusion criteria

*Contraindicated for IPG under Japanese guidelines
*Patients who are currently included in another cardiac clinical study
*Patients with expected life period of less than 27 months
*Patients who might undergo heart transplantation in next 27 months.

Target sample size

1364


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Eiichi Watanabe

Organization

Fujita Health University

Division name

Cardiovascular Internal Medicine

Zip code


Address

1-98, Denrakuga-kubo, Kutsukake-cho, Toyoake-city, Aichi, Japan

TEL

0562932312

Email

enwatan@fujita-hu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yoshiko Ishiwatari

Organization

Biotronik Japan

Division name

Cliniacl Affair

Zip code


Address

1-19-19 Ebisu, Shibuya-ku, Tokyo

TEL

03-3473-7478

Homepage URL


Email

yoshiko.ishiwatari@biotronik.com


Sponsor or person

Institute

Biotronik Japan

Institute

Department

Personal name



Funding Source

Organization

Biotronik Japan

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

NCT01523704

Org. issuing International ID_1

Clinicaltrials.gov

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 02 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2011 Year 12 Month 01 Day

Date of IRB


Anticipated trial start date

2012 Year 01 Month 01 Day

Last follow-up date

2015 Year 12 Month 31 Day

Date of closure to data entry

2016 Year 01 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 02 Month 24 Day

Last modified on

2014 Year 07 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008690


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name